Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2023-08-23 00:00:00 ET · period of report 2023-08-21 · accession 0001610717-23-000234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2023-08-23 | 2023-08-21 | IDYA | Stone Paul A. | CFO | S - Sale | $26.40 | -978 | 14.3K | -6% | -$25.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-21 | S | D | 978 | $26.40 | 14,303 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $26.38 to $26.4175, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |